Details for New Drug Application (NDA): 090502
✉ Email this page to a colleague
NDA 090502 describes LACTULOSE, which is a drug marketed by Cumberland Pharms, Pai Holdings, Ani Pharms, Apozeal Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Fresenius Kabi, Hikma, Lannett Co Inc, Morton Grove, Paco, Pharm Assoc, Pharmobedient, Taro, Vistapharm Llc, Bajaj, Pai Holdings Pharm, Roxane, Sciegen Pharms Inc, and Solvay, and is included in twenty-four NDAs. It is available from twenty-one suppliers. Additional details are available on the LACTULOSE profile page.
The generic ingredient in LACTULOSE is lactulose. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lactulose profile page.
The generic ingredient in LACTULOSE is lactulose. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lactulose profile page.
Summary for 090502
| Tradename: | LACTULOSE |
| Applicant: | Fresenius Kabi |
| Ingredient: | lactulose |
| Patents: | 0 |
Pharmacology for NDA: 090502
| Mechanism of Action | Acidifying Activity Osmotic Activity |
| Physiological Effect | Stimulation Large Intestine Fluid/Electrolyte Secretion |
Medical Subject Heading (MeSH) Categories for 090502
Suppliers and Packaging for NDA: 090502
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LACTULOSE | lactulose | SOLUTION;ORAL, RECTAL | 090502 | ANDA | Fresenius Kabi Austria GmbH | 18124-002 | 18124-002-16 | 473 mL in 1 BOTTLE (18124-002-16) |
| LACTULOSE | lactulose | SOLUTION;ORAL, RECTAL | 090502 | ANDA | Actavis Pharma, Inc. | 45963-438 | 45963-438-64 | 473 mL in 1 BOTTLE (45963-438-64) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL, RECTAL | Strength | 10GM/15ML | ||||
| Approval Date: | Jan 25, 2012 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
